St. John’s wort and Kava in treating major depressive disorder with comorbid anxiety : a randomised double-blind placebo-controlled pilot trial

Objective - We report the first randomised controlled trial (RCT) using a combination of St. John’s wort (SJW) and Kava for the treatment of major depressive disorder (MDD) with comorbid anxiety. Methods - Twenty-eight adults with MDD and co-occurring anxiety were recruited for a double-blind RCT. After a placebo run-in of 2 weeks, the trial had a crossover design testing SJW and Kava against placebo over two controlled phases, each of 4 weeks. The primary analyses used intention-to-treat and completer analyses. Results - On both intention-to-treat ( p¼0.047) and completer analyses ( p¼0.003), SJW and Kava gave a significantly greater reduction in self-reported depression on the Beck Depression Inventory (BDI-II) over placebo in the first controlled phase. However, in the crossover phase, a replication of those effects in the delayed medication group did not occur. Nor were there significant effects on anxiety or quality of life. Conclusion - There was some evidence of antidepressant effects using SJW and Kava in a small sample with comorbid anxiety. Possible explanations for the absence of anxiolysis may include a potential interaction with SJW, the presence of depression, or an inadequate dose of Kava.

Kava Anxiety Depression Spectrum Study (KADSS): a mixed methods RCT using an aqueous extract of Piper methysticum

Objectives: To report on the design, significance and potential impacts of the first documented human clinical trial assessing the anxiolytic and thymoleptic efficacy of an aqueous monoextract of Piper methysticum (kava). The significance of the qualitative element of our clinical trial is also explored. The Kava Anxiety Depression Spectrum Study (KADSS) is a 3-week placebocontrolled, double-blind, cross-over trial involving 60 adult participants (18—65) with elevated stable anxiety and varying levels of depressive symptoms. Aims: The aims of KADSS are: (1) to determine whether an aqueous standardised extract of kava is effective for the treatment of anxiety; (2) to assess the effects of kava on differing levels of depression; and (3) to explore participants’ experience of taking kava via qualitative research. The study also provides preliminary assessment of the safety of an aqueous extract of kava in humans. Conclusion: If results reveal that the aqueous kava preparation exerts significant anxiolytic effects and appears safe, potentially beneficial impacts may occur. Data supporting a safe and effective kava extract may encourage a re-introduction of kava to Europe, UK and Canada. This may provide a major socioeconomic benefit to Pacific Island nations, and to sufferers of anxiety disorders.

The Kava Anxiety Depression Spectrum Study (KADSS): A randomized, placebo-controlled, cross-over trial using an aqueous extract of Piper methysticum.

Rationale: Piper methysticum (Kava) has been withdrawn in European, British, and Canadian markets due to concerns over hepatotoxic reactions. The WHO recently recommended research into “aqueous” extracts of Kava. Objective: The objective of this study was to conduct the first documented human clinical trial assessing the anxiolytic and antidepressant efficacy of an aqueous extract of Kava. Design and participants: The Kava Anxiety Depression Spectrum Study was a 3-week placebo-controlled, double-blind crossover trial that recruited 60 adult participants with 1 month or more of elevated generalized anxiety. Five Kava tablets per day were prescribed containing 250 mg of kavalactones/day. Results: The aqueous extract of Kava reduced participants' Hamilton Anxiety Scale score in the first controlled phase by −9.9 (CI = 7.1, 12.7) vs. −0.8 (CI = −2.7, 4.3) for placebo and in the second controlled phase by −10.3 (CI = 5.8, 14.7) vs. +3.3 (CI = −6.8, 0.2). The pooled effect of Kava vs. placebo across phases was highly significant (p < 0.0001), with a substantial effect size (d = 2.24, η² [sub]p[sub] = 0.428). Pooled analyses also revealed highly significant relative reductions in Beck Anxiety Inventory and Montgomery–Asberg Depression Rating Scale scores. The aqueous extract was found to be safe, with no serious adverse effects and no clinical hepatotoxicity. Conclusions: The aqueous Kava preparation produced significant anxiolytic and antidepressant activity and raised no safety concerns at the dose and duration studied. Kava appears equally effective in cases where anxiety is accompanied by depression. This should encourage further study and consideration of globally reintroducing aqueous rootstock extracts of Kava for the management of anxiety.

Kava and St. John's wort : current evidence for use in mood and anxiety disorders

Background: Mood and anxiety disorders pose significant health burdens on the community. Kava and St John’s wort (SJW) are the most commonly used herbal medicines in the treatment of anxiety and depressive disorders, respectively. Objectives: To conduct a comprehensive review of kava and SJW, to review any evidence of efficacy, mode of action, pharmacokinetics, safety and use in Major Depressive Disorder (MDD), Bipolar Disorder (BP), Seasonal Affective Disorder (SAD), Generalized Anxiety Disorder (GAD), Social Phobia (SP), Panic Disorder (PD), Obsessive-Compulsive Disorder (OCD), and Post Traumatic Stress Disorder (PTSD). Methods: A systematic review was conducted using the electronic databases MEDLINE, CINAHL, and The Cochrane Library during late 2008. The search criteria involved mood and anxiety disorder search terms in combination with kava, Piper methysticum, kavalactones, St John’s wort, Hypericum perforatum, hypericin and hyperforin. Additional search criteria for safety, pharmacodynamics , and pharmacokinetics was employed. A subsequent forward search was conducted of the papers using Web of Science cited reference search. Results: Current evidence supports the use of SJW in treating mild-moderate depression, and for kava in treatment of generalized anxiety. In respect to the other disorders, only weak preliminary evidence exists for use of SJW in SAD. Currently there is no published human trial on use of kava in affective disorders, or in OCD, PTSD, PD or SP. These disorders constitute potential applications that warrant exploration. Conclusions: Current evidence for herbal medicines in the treatment of depression and anxiety only supports the use of Hypericum perforatum for depression, and Piper methysticum for generalized anxiety.

An explorative qualitative analysis of participants' experience of using kava versus placebo in an RCT. (Clinical report)

Many randomised controlled trials (RCT) have been conducted using Piper methysticum (kava), however no qualitative research exploring the experience of taking kava during a clinical trial has previously been reported. ---------- Patients and methods: A qualitative research component (in the form of semi structured and open ended written questions) was incorporated into an RCT to explore the experiences of those participating in a clinical trial of kava. The written questions were provided to participants at weeks 2 and 3 (after randomisation, after each controlled phase). The researcher and participants were blinded as to whether they were taking kava or placebo. Two open ended questions were posed to elucidate their experiences from taking either kava or placebo. Thematic analysis was undertaken and researcher triangulation employed to ensure analytical rigour. Key themes after the kava phases were a reduction in anxiety and stress, and calming or relaxing mental effects. Other themes related to improvement in sleep and in somatic anxiety symptoms. ---------- Results: Kava use did not cause any serious adverse reactions although a few respondents reported nausea or other gastrointestinal side effects. This represents the first documented qualitative investigation of the experience of taking kava during a clinical trial. The primary themes involved anxiolytic and calming effects, with only a minor theme reflecting side effects. Our exploratory qualitative data was consistent with the significant quantitative results revealed in the study and provides additional support to suggest the trial results did not exclude any important positive or negative effects (at least as experienced by the trial participants).

Cucumber mosaic virus infection of kava (Piper methysticum) and implications for cultural control of kava dieback disease

Cucumber mosaic virus (CMV) was found by reverse transcription polymerase chain reaction (RT-PCR) to be not fully systemic in naturally infected kava (Piper methysticum) plants in Fiji. Twenty-six of 48 samples (54%) from various tissues of three recently infected plants were CMV-positive compared with 7/51 samples (14%) from three long-term infections (plants affected by dieback for more than 1 year). The virus was also found to have a limited ability to move into newly formed stems. CMV was detected in only 2/23 samples taken from re-growth stems arising from known CMV infected/dieback affected plants. Mechanical inoculation experiments conducted in Fiji indicate that the known kava intercrop plants banana (Musa spp.), pineapple (Ananas comosus), peanut (Arachis hypogaea) and the common weed Mikania micrantha are potential hosts for a dieback-causing strain of CMV It was not possible to transmit the virus mechanically to the common kava intercrop plants taro (Colocasia esculenta), Xanthosoma sp., sweet potato (Ipomoea batatas), yam (Dioscorea alata), papaya (Carica papaya) or the weed Momordica charantia. Implications of the results of this research on a possible integrated disease management strategy are discussed.

Avaliação da atividade neuroprotetora do extrato de kava (Piper methysticum) em modelos in vitro de lesão celular

As doenças cerebrovasculares, popularmente conhecidas como derrames, são uma das principais causas de morbidade e mortalidade entre adultos e idosos. Contudo, muitos pacientes que sofrem derrame sobrevivem e experimentam as conseqüências do insulto por muitos anos, muitas vezes a nível emocional, motor ou intelectual. Dentre estas lesões, destaca-se a isquemia cerebral. Existem modelos experimentais de isquemia cerebral in vivo e in vitro. Os modelos in vitro são realizados em culturas ou fatias de tecido cerebral submetidas à Privação de Oxigênio e Glicose (POG), que mimetizam condições traumáticas similares, mas não idênticas às produzidas in vivo. A investigação da atividade de substâncias potencialmente neuroprotetoras a partir da comparação da morte celular entre culturas ou fatias de tecido cerebral controle e tratadas é facilitada neste tipo de modelo experimental. Após a injúria, as culturas são expostas a métodos de avaliação da viabilidade ou dano celular como, por exemplo, o corante fluorescente iodeto de propídeo, que marca seletivamente células mortas ou em curso de morte, ou MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazoliumbromide) que mede a viabilidade mitocondrial possibilitando uma posterior quantificação. As plantas são uma fonte importante de produtos naturais biologicamente ativos, muitos dos quais se constituem em modelos para a síntese de um grande número de fármacos. Um exemplo é a planta kava-kava ou somente kava (Piper Methysticum) a qual chamou a atenção dos pesquisadores devido à sua utilização nas ilhas do Pacífico sul. Foi demonstrada a possibilidade da kava possuir uma variedade de atividades farmacológicas importantes, entre elas a atividade de neuroproteção Esse trabalho tem como objetivo avaliar a atividade neuroprotetora do extrato de kava-kava (Piper methysticum) em modelos in vitro de morte neuronal em fatias de hipocampo de ratos, investigar o envolvimento da proteína de choque térmico HSP27 (Heat Shock Protein) no processo de morte e neuroproteção induzida pela kava, bem como investigar o efeito da lesão induzida por POG sobre o imunoconteúdo da proteína Oxido Nítrico Sintase induzível (iNOS). Os resultados dos experimentos por nós realizados nas culturas organotípicas submetidas à POG por 40 minutos e tratadas com extrato de kava (7µg/ml) demonstraram uma significativa redução, na ordem de 58% na intensidade da morte neuronal na região CA1 do hipocampo em resposta à injúria. Em fatias hipocampais submetidas à POG por 60 minutos a adição do extrato de kava 7µg/ml aumentou em 15% a viabilidade celular, confirmando a atividade neuroprotetora sugerida para esta planta. As culturas expostas à POG e tratadas com kava apresentaram um aumento significativo no imunoconteúdo da proteína HSP27, esse aumento é acompanhado de um aumento da fosforilação, uma vez que a percentagem de proteína fosforilada se mantém igual. As fatias lesionadas tratadas com kava apresentaram uma diminuição significativa no imunoconteúdo da iNOS na ordem de 35 % em relação as fatias lesionadas tratadas com DMSO (Dimetilsulfoxido). Estes dados podem sugerir que um dos mecanismos da neuroproteção observada para o extrato de kava, possa envolver essas proteínas.

Avaliação toxicológica da preparação fitoterápica contendo Piper methysticum Forst, piperaceae (Kava Kava ) sobre o desenvolvimento pré-natal de ratos winstar.

A kava kava (Piper methysticum Forst), pertencente à família Piperaceae, é utilizada para diminuir a ansiedade e medo e tratar distúrbios comportamentais. É um fitoterápico utilizado em vários países, entretanto pouco se sabe, sobre seus efeitos no desenvolvimento embrionário. O presente trabalho avaliou o possível efeito teratogênico da formulação fitoterápica contendo Piper methysticum Forst durante o período de organogênese em ratas Wistar. As ratas foram tratadas com 0mg.kg –1 (controle), 5mg.kg –1 ; 35mg.kg –1 e 50mg.kg –1 da preparação fitoterápica (kava kava®), por via oral, do 6° ao 15° dia de prenhez. Os resultados revelaram ausência de toxicidade sistêmica e reprodutiva nas variáveis avaliadas, fundamentados pela ausência de alterações no desenvolvimento ponderal, consumos de ração e água, na massa relativa dos órgãos, nas reabsorções embrionárias, na massa corporal, na vitalidade, no número de fetos por progenitora e nas alterações macroscópicas externas e esqueléticas dos fetos. Adicionalmente as enzimas alanina aminotrasferase (ALT) e fosfatase alcalina (FA) foram determinadas no soro das ratas tratadas, para avaliar o possível efeito hepatotóxico da preparação fitoterápica. Não houve alteração na atividade das enzimas ALT e FA, bem como alterações histopatológicas do fígado das ratas, não confirmando a hepatotoxicidade. Conclui-se que o fitoterápico kava kava, até 35mg.kg –1, não determina o aparecimento de teratogenicidade.

Kavaʼidi osmaniye /

Mode of access: Internet.

Adjuvant use of nutritional and herbal medicines with antidepressants, mood stabilizers and benzodiazepines

Adjuvant use of nutritional and herbal medicines has potential to increase the efficacy of synthetic pharmaceuticals, and perhaps also decrease their side-effects by allowing lower doses to be prescribed. We evaluated current evidence for adjuvant use of nutritional and herbal medicines with antidepressants, mood stabilizers and benzodiazepines; and explored novel future areas of research. The paper also critiques current evidence for co-administration of St. John’s wort with synthetic antidepressants. We performed a systematic search of MEDLINE, CINAHL, PsycINFO, The Cochrane database, China National Knowledge Infrastructure and the Chinese Science Citation Database. Search results were supplemented by a review of reference lists and a forward search using the Web of Science. Where possible we calculated effect sizes. Encouraging evidence exists for the use of omega-3 fatty acids, SAMe, folic acid and l-tryptophan adjuvantly with antidepressants to enhance response and improve efficacy. Various nutrients also have emerging evidence as effective adjuncts with antipsychotics and mood stabilizers. While some evidence supports nutritional adjuvancy with various psychopharmacotherapies, adjuvant use of herbal therapies has not been sufficiently studied to warrant standard clinical application. This remains a promising area of research via robust, safety-conscious studies.

An outbreak of salmonellosis linked to a marine turtle

On 18 September 1998 the Centre for Disease Control (CDC), Darwin was notified of an outbreak of gastroenteritis predominantly affecting adults in a Top End coastal community. There had been no previous presentations to the community clinic in the month of September with vomiting or diarrhoea. On 14 September, a green turtle (Chledonia mydas) was cooked and distributed throughout the community. Water collected from a water hole near the community (known as the aerator) was used as drinking water at the cook site and to cook the meat. In addition, there were reports that kava, a plant derived tranquilliser,1 had been consumed the night before using water from the same source. An investigation was conducted to determine the aetiology and source and to instigate prevention and control measures.